Eliminating the use of intravenous glass bottles using a FOCUS-PDCA model and providing a practical stability reference guide

Maraiki, Fatma; Farooq, Faiyaz; Ahmed, Mohamed M.

doi:10.1111/ijpp.12245

Cited by 11 publications

(19 citation statements)

References 30 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of studies (n= 34) were published in international journals 14,[17][18][19]21,24,25,[27][28][29][30][35][36][37][38][39][40][41][42][43][45][46][47][48][50][51][52][53][54][57][58][59][60][61] and the remaining 15 studies were published in journals based in G.C.C. countries.…”

Section: Publication Characteristicsmentioning

confidence: 99%

“…15,16,20,22,23,26,[31][32][33][34]44,49,55,56,62 Thirty seven studies were published in medical journals, [14][15][16][17][18][19][20][22][23][24][25][26][28][29][30][31][32][33]36,38,40,41,44,46,49,50,[52][53][54][55][56][57][58][59][60][61][62] 7 in non-medical journals …”

Section: Publication Characteristicsmentioning

confidence: 99%

“…The earliest study was published in 1991 14 and the most recent study was published in December 2017. 62 The majority studies were published in 2016 [49][50][51][52][53][54][55][56] ( Figure 2).…”

Section: Publication Characteristicsmentioning

confidence: 99%

“…25,27,35,60 ; these included Canada, 25 USA , 27 UK 35 and Poland. 60 The primary author in 40 of the included studies (81.6%) had a medical or clinical background [14][15][16][17][18][19][20][21][22][23][24][26][27][28][29][30][32][33][34][36][37][38][39][40][41][42][43][44][45][46][47]49,51,53,[55][56][57][58][59]61 , compared with 4 studies were the primary background was health economics 48,52,60,…”

Section: Primary Author Characteristicsmentioning

confidence: 99%

“…Thirty four studies were national, 14,15,[18][19][20][21][22][23][24]26,[29][30][31][32][33][34][38][39][40][41][45][46][47][48][49][50][51][52][53][54][55][59][60][61][62] 9 studies were sub-national (where they covered cities of interest in a country) 16,28,36,42,44,50,[56][57][58] and 6 studies were multinational. 17,25,27,35,37,43 Eighteen of the studies published were based on data from Saudi Arabia, …”

Section: Geographical Location Of Data Collectionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries

Eljilany¹,

El‐Dahiyat

Curley

et al. 2018

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

Section: Publication Characteristicsmentioning

confidence: 99%

Section: Publication Characteristicsmentioning

confidence: 99%

Section: Publication Characteristicsmentioning

confidence: 99%

Section: Primary Author Characteristicsmentioning

confidence: 99%

Section: Geographical Location Of Data Collectionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries

Eljilany¹,

El‐Dahiyat

Curley

et al. 2018

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion

2019

View full text Add to dashboard Cite

Objective PF-06438179/GP1111 (PF-SZ-IFX) is an infliximab biosimilar. We evaluated the extended in-use physicochemical and biological stability of PF-SZ-IFX upon preparation for intravenous infusion. Methods Two batches of PF-SZ-IFX were reconstituted to a concentration of 10 mg/mL and subsequently diluted to 0.4 and 4.0 mg/mL, representing the clinically relevant range for intravenous infusion. Dilution was performed in polyethylene saline infusion bags, which are commonly used in clinical practice. To simulate product handling under worst-case conditions, reconstituted solutions were stored for up to 30 days at 5 ± 3 °C and up to 14 days at 25 ± 2 °C (60 ± 5% relative humidity); diluted solutions were stored for up to 30 days under the same sets of conditions. Physicochemical and biological stability were evaluated according to pH, osmolality, appearance, particulate content, protein concentration, proportions of molecular weight variants and charge variants and potency. Standard and state-of-the-art analytical techniques were employed, including imaged isoelectric focusing, size exclusion chromatography, reducing sodium dodecyl sulphate capillary electrophoresis and functional cell-based bioassay. Results Across batches and concentrations of PF-SZ-IFX, all parameters resided within the predefined acceptance criteria, including pH, osmolality, particulate content, clarity, protein concentration, molecular weight variants, charge variants and potency, for up to 30 days under both storage conditions tested (up to 14 days for reconstituted samples stored at 25 ± 2 °C). Conclusions Physicochemical and biological analyses demonstrated that the infliximab biosimilar PF-SZ-IFX was not affected by extended storage of the diluted preparations used for intravenous infusion.

show abstract

Implementing ergonomics interventions in the endoscopy suite

Ali

Samarasena

2019

Techniques in Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Eliminating the use of intravenous glass bottles using a FOCUS-PDCA model and providing a practical stability reference guide

Abstract: The elimination of glass bottles within the institution resulted in a significant cost saving. The use of FOCUS-PDCA model can help healthcare institution achieve significant improvements in process and realize significant cost savings.

Cited by 11 publications

References 30 publications

Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries

Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries

Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion

Implementing ergonomics interventions in the endoscopy suite

Contact Info

Product

Resources

About